Not enough data
Eliza Slawther's articles predominantly focus on legal policy regulation and government announcements within the healthcare and pharmaceutical industry. Her coverage revolves around institutions such as EMA (European Medicines Agency) and FDA (Food and Drug Administration), with a specific emphasis on drug development, AI regulation, and their impacts.
Given her emphasis on government announcements and regulatory developments in the pharma industry, she would likely be interested in pitches from experts who can provide analysis or commentary about new regulations, policies, or major decisions made by these agencies. Sources well-versed in the workings of EMA, FDA, drug approval processes or AI applications in healthcare are likely to attract her attention.
As Eliza's geographic focus is not specified but given the nature of her coverage related to European agencies like EMA along with global entities like FDA suggests an international outlook for potential stories.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Eliza Slawther, Jun By
The European Commission wants to eventually fully phase out the use of animal tests in chemical safety assessments. Identifying and addressing regulatory gaps around the validation of new methodologies will be a key part of the strategy, a commission policy officer has said.
By: Jul By, Eliza Slawther
The European Medicines Agency is planning to overhaul its guideline on the clinical evaluation of antifungal agents for invasive fungal diseases for the first time in more than 15 years, a move that could open the door to more flexibility around alternative trial designs.
By: Jul By, Eliza Slawther
The NC3Rs, an independent organization tasked with driving the uptake of animal testing alternatives in the UK, is asking people working in innovative research to propose areas where adopting or developing new approach methodologies would be most useful.
By: Eliza Slawther, Jul By
The UK drug regulator, the MHRA, says it does not have access to the regulatory-grade data required to fulfil its safety obligations, but hopes the government's planned Health Data Research Service could rectify access issues.
By: Eliza Slawther, Jul By
The UK drug regulator supports the use of real-world data for regulatory purposes, but says marketing authorization applicants need better access to high-quality, curated datasets.
By: Eliza Slawther, Jul By
The upcoming EU Biotech Act has prompted a coalition of more than 200 life sciences investors, companies and research organizations to set out the challenges that policymakers must address to strengthen Europe's life sciences ecosystem.
England's health technology assessment (HTA) institute, NICE, says the benefits of Amgen's non-small-cell lung cancer drug Lumykras are too small relative to its costs to be routinely reimbursed through the National Health Service.
By: Jul By, Eliza Slawther
Revolution Medicines' daraxonrasib for metastatic pancreatic cancer is undergoing a “phased review” by the European Medicines Agency, an approach that the EU plans to roll out under the upcoming pharma legislation reform to accelerate high-priority drug approvals.
By: Jul By, Eliza Slawther
Andy Burnham is set to become Britain's new prime minister from next week, a leadership change that could “further enlighten” the nation's life sciences industry, according to member of parliament and former health minister Zubir Ahmed.
By: Eliza Slawther, Jul By
Regulators must focus on building networks that work on a global scale to improve access to health data for pharmaceutical researchers, work that may be unexciting but will help drive innovation, a biomedical data expert says.
